COVACTA trial raises questions about tocilizumab's benefit in COVID-19

B Furlow - The Lancet Rheumatology, 2020 - thelancet.com
Hoffmann-La Roche has announced disappointing results from its much-anticipated phase 3
COVACTA trial of tocilizumab, raising questions about the efficacy of interleukin (IL)-6 …
被引用次数：153 相关文章
[HTML] nih.gov

[HTML][HTML] COVACTA trial raises questions about tocilizumab's benefit in COVID-19

B Furlow - The Lancet. Rheumatology, 2020 - ncbi.nlm.nih.gov
COVACTA trial raises questions about tocilizumab's benefit in COVID-19 - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …

COVACTA trial raises questions about tocilizumab's benefit in COVID-19.

B Furlow - The Lancet. Rheumatology, 2020 - europepmc.org
Hoffmann-La Roche has announced disappointing results from its much-anticipated phase 3
COVACTA trial of tocilizumab, raising questions about the efficacy of interleukin (IL)-6 …
[HTML] thelancet.com

[HTML][HTML] COVACTA trial raises questions about tocilizumab's benefit in COVID-19

B Furlow - The Lancet Rheumatology, 2020 - thelancet.com
Hoffmann-La Roche has announced disappointing results from its much-anticipated phase 3
COVACTA trial of tocilizumab, raising questions about the efficacy of interleukin (IL)-6 …

[引用][C] COVACTA trial raises questions about tocilizumab's benefit in COVID-19

B Furlow - The Lancet. Rheumatology, 2020 - pubmed.ncbi.nlm.nih.gov